التفاصيل البيبلوغرافية
| العنوان: |
Monovalent SARS-CoV-2 mRNA Vaccine Does not Boost Omicron-Specific Immune Response in Diabetic and Control Pediatric Patients. |
| المؤلفون: |
Sariol, Alan1 (AUTHOR), Vickers, Molly A1 (AUTHOR), Christensen, Shannon M2 (AUTHOR), Weiskopf, Daniela3 (AUTHOR), Sette, Alessandro3 (AUTHOR), Norris, Andrew W2,4 (AUTHOR), Tansey, Michael J2,4 (AUTHOR), Pinnaro, Catherina T2,4 (AUTHOR), Perlman, Stanley1 (AUTHOR) Stanley-perlman@uiowa.edu |
| المصدر: |
Journal of Infectious Diseases. 4/15/2024, Vol. 229 Issue 4, p1059-1067. 9p. |
| مصطلحات موضوعية: |
*COVID-19 vaccines, *GLYCEMIC control, *SARS-CoV-2 Omicron variant, *IMMUNE response, *CHILD patients |
| مستخلص: |
While the immunogenicity of SARS-CoV-2 vaccines has been well described in adults, pediatric populations have been less studied. In particular, children with type 1 diabetes are generally at elevated risk for more severe disease after infections, but are understudied in terms of COVID-19 and SARS-CoV-2 vaccine responses. We investigated the immunogenicity of COVID-19 mRNA vaccinations in 35 children with type 1 diabetes (T1D) and 23 controls and found that these children develop levels of SARS-CoV-2 neutralizing antibody titers and spike protein-specific T cells comparable to nondiabetic children. However, in comparing the neutralizing antibody responses in children who received 2 doses of mRNA vaccines (24 T1D; 14 controls) with those who received a third, booster dose (11 T1D; 9 controls), we found that the booster dose increased neutralizing antibody titers against ancestral SARS-CoV-2 strains but, unexpectedly, not Omicron lineage variants. In contrast, boosting enhanced Omicron variant neutralizing antibody titers in adults. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
